In patients undergoing chemotherapy systemic toxicity remains the major limitation to adequate dosing. The ability to predict adverse events prior to drug administration, and to provide individualized treatment, is likely to have a significant impact on clinical outcomes and quality of life, particularly in the palliative setting. 'Pharmaco-metabonomics' -using pre-treatment profiles of endogenous metabolite levels to predict the metabolic fate and toxicity of drugspotentially offers phenotypic information not captured by genetic profiling. A patient's response to treatment relies on a complex array of genetic and environmental factors and this approach has the ability to identify in a non-invasive manner a downstream profile that describes the 'current state' biological system, beyond the potential state defined by the genome. In the future models based on the combination of both pharmaco-genetic and pharmaco-metabonomic information using up-and down-stream data can help delineate the optimum therapeutic pathway for the individual patient.
Introduction
Metabolic profiling (metabonomics/metabolomics) is a flexible approach that can be used to investigate in a systematic manner the metabolic composition of cells, tissues and biofluids (1) (2) (3) (4) .
It has recently been demonstrated that pre-treatment biofluid metabolic profiles can be used to predict the metabolic fate and toxicity of drugs in vivo, specifically for acetaminophen exposure in rodents (5), an observation subsequently shown to translate to man (6, 7). This strategy, termed 'pharmaco-metabonomics', potentially offers phenotypic information not captured by genetic profiling that can be used to predict pharmacology. In the study by Winnike et al. (7) a combination of both the early drug metabolite profile and observed changes in common urinary endogenous metabolites were able to identify a subpopulation of individuals who experienced ALT elevation in response to 4g/day acetaminophen, several days before the phenotype was apparent by conventional clinical chemistry. H NMR spectra were acquired using a Bruker DRX600C spectrometer (Bruker Biospin, Rheinstetten, Germany), operating at a temperature of 300K, at a 1 H NMR frequency of 600.13MHz using automatic sample delivery into a 5mm TXI NMR probe.
Materials and Methods

Patients
Gradient shimming was performed prior to acquisition of spectra. 1 H NMR spectra of the samples were acquired using the Carr-Purcell-Meiboom-Gill (CPMG) and 1D presaturation pulse sequences and were the sum of 256 free induction decays (FIDs) collected into 32k datapoints with a spectral width of 12019.230 Hz.
Data treatment and statistical analysis. Exponential line broadening (1Hz), Fourier
Transformation and manual spectral phasing and linear baseline correction were conducted using XWIN NMR 3.5 software (Bruker). Data were imported and manipulated in Matlab (Mathworks) using in-house software 'NMRProc' and 'Metaspectra' written and compiled by Dr. T.M.D. Ebbels, Dr H.C.Keun, Mr. J.T. Pearce, and Dr O. Cloarec. Two spectra were excluded due to poor spectral quality. The remaining spectra were calibrated to glucose at 5.23ppm using an automated calibration script (26), normalized (27) (by the median fold change to the median spectrum) and 'binned' in Matlab (this was done by selective 'peak-picking'; the data was visually assessed and 89 metabolite resonances identified). Varying bin widths were allocated based upon metabolite resonances and regions. Binned data was exported to SIMCA (Umetrics) for multivariate analysis. For relative quantification of the individual metabolites, signals were integrated with local linear baseline correction applied.
Statistical analyses were undertaken using SPSS Statistics version 17.0 (SPSS Inc.) and Microsoft Excel. Differences between metabolite integral regions were assessed by T-test (assuming unequal variance and corrected for multiple testing, q<0.05). Correlation between metabolite regions and severity of toxicity was assessed using Kendall's tau (rank-based, 2
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Results
Patients and treatment outcome. NMR spectra of sufficient quality could not be obtained from two samples; therefore, metabonomic-outcome analyses were conducted on 52 patients. The demographic and clinical characteristics of the patients are summarized in Table 1 -7 months). The median number of cycles received was 4.9 (range 1-8 cycles). As previously published, the response rate to therapy was 28% (95% CI: 15.7 -40.3) (24) .
Clinically significant toxicities are reported in Table 2 . Overall, capecitabine was well tolerated with no grade 4 non-hematologic or grade 3/4 hematologic adverse events recorded. There were no adverse event-related deaths during the study. The most common treatment-related adverse events were diarrhoea, hand-foot syndrome, and fatigue. Toxicity led to the cessation of treatment in eight patients (15%) and of these, five patients ceased treatment after cycle 1. The most frequent adverse event leading to discontinuation was grade 3 diarrhoea. These patients were included in the final analysis.
Relationship between
H NMR metabolic profile and toxicity
We hypothesised that there is a relationship between features in the 1 H NMR metabolic profile of sera taken from patients pre-treatment, and subsequent toxicity as a result of capecitabine exposure. Figure 1 is aliphatic region of the mean CPMG spectrum of the sera collected from patients who experienced no toxicity overlaid with the mean spectrum of sera from those who experienced severe toxicity (grade 3) over the total treatment period. The CPMG experiment attenuates signals from macromolecules, in particular serum proteins, allowing a better focus on metabolic features. Visual inspection indicated that there were major differences on average between the spectra, including resonances from lipid fatty acid chains, glutamate, glutamine, polyunsaturated fatty acids (PUFA), and choline phospholipids.
Following these initial visual indications, the CPMG spectrum for each patient was integrated at 89 targeted spectral regions encompassing resolved resonances apparent by visual inspection.
As an initial test of the hypothesis, a partial least squares-discrimination analysis (PLS-DA) was performed using the integrated To define more precisely which spectral features were significantly associated with toxicity from capecitabine, we assessed the mean difference in intensity of each metabolite resonance (89 resonances, the same as used for the multivariate analysis) between the grade 0 and grade 3 groups. Table 3 shows the 1 H NMR resonances that were identified as being significantly different between the two patient groups. These included fatty acid chains, polyunsaturated fatty acids, choline phospholipid, valine, adipic acid, tyrosine and one unassigned resonance. We then applied the method of Benjamini and Holchberg (28) to evaluate the false discovery rate (FDR) and P-value corrected for multiple testing (q). Four spectral regions were still considered significant (q<0.05) after multiple testing correction, corresponding to the following moieties; -CH3 (δ 0.8-0.86); (-CH 2 -) n (δ 1.21-1.24); =CH-CH 2 -CH= (δ 2.72-2.78), and N(CH 3 ) 3 (δ 3.2-3.2).
The levels of these resonances were all higher in the patients who experienced severe toxicity compared to no toxicity. These moieties were assigned to LDL-like lipid particles (δ0. spectrum of human plasma and serum has been comprehensively described in many publications which show that the metabolites detectable by NMR in serum are highly consistent and that significant variation in chemical shift due to inter-sample variation in pH, temperature or ionic strength is also minimal in this biological matrix.
We also compared the CPMG spectra to those acquired using a standard pre-saturation sequence and observed a similar or lower magnitude of differences between the toxicity groups ( Figure 3 ). As the CPMG suppresses high-molecular weight species such lipoprotein particles, this suggested that the CH 2 and CH 3 moieties were from smaller, higher density particles such LDL, rather than very low density lipoprotein (VLDL). Finally, the fact that choline phospholipidbased and polyunsaturated fatty acid-based resonances were observed this also supports the assignment of the lipid-based resonances to LDL, as phosphatidylcholine is the main phospholipid in LDL, and the most common fatty acyl chain in LDL is from a polyunsaturated fatty acid. Despite this there is substantial evidence to suggest that NMR lipid profiles are sensitive to subtle differences in lipoprotein particle size and composition that is not reflected by conventional estimates of lipoprotein particle distribution (30, 31) and hence we define our lipid profile primarily by resonance frequency rather than lipoprotein species.
Having identified a pharmaco-metabonomic lipid profile discriminating between the most extreme toxicity groups (grade 0 and grade 3), we observed that those patients experiencing 
Discussion
In the last few years the 1 H NMR-based metabolic profiling approach has shown potential in the prediction of response to treatment (pharmaco-metabonomics) using the fate of paracetamol in rats and man as an example of the method in principle (6, 7, 33). These studies highlight the predictive potential of metabonomics-based personalised health care in a clinical setting. The current challenge is to assess how well this pharmaco-metabonomic approach translates to the clinic. A patient's response to a given chemotherapeutic treatment relies on a complex array of factors that are broadly encompassed by both the genome and environment. Unlike pharmacogenomics which focuses on the genetic/enzymatic factors in disease and drug metabolism, pharmaco-metabonomics interrogates the metabolism of a particular biofluid or tissue from a patient, providing a profile that is derived from combined genetic and environmental influences (34). The advantage of this approach is the ability to identify a downstream profile that provides a picture of the biological system in its 'current state', as opposed to a potential state (as may be indicated by a genetic factor).
Previous research using metabolic profiling of biofluids in the oncology setting has focused on identifying panels of metabolites that show potential for aiding current diagnostic methodology (11). To our knowledge this is the first study to report the predictive capacity of metabonomics to allow identification of toxicity severity secondary to chemotherapy using pre-treatment serum samples from patients with colorectal cancer. In this study we showed an association with lipidbased resonances and increased toxicity experienced by patients. This study highlights the possible role of this technique in individualizing chemotherapy regimens to avoid intolerable side-effects, thereby improving treatment outcomes. between low lean body mass, as measured by CT, and worse toxicity with 5-FU, lending support to our findings (32). Therefore, whilst our findings of weight and toxicity are interesting they raise the need further investigation with more detailed anthropometric measures in a larger patient population.
We chose to study the metabonomic profile of patients prior to receiving capecitabine with the primary aim to identify a metabonomic profile predictive of toxicity. Whilst these results are provocative they need to be validated in larger confirmatory studies. The results of this study will act as a training set that will be validated in a larger patient group to confirm the utility of metabonomics as a predictor of toxicity prior to patients receiving chemotherapy. From this planned future study it will be possible to more accurately define specific cut-off values for spectral species above which patients presenting to the clinic would be likely to experience toxicity. Chemotherapy doses could then be prospectively altered. These studies will be difficult to conduct with single agent capecitabine as combination therapy now remains the mainstay of treatment in colorectal cancer, and furthermore individual drugs themselves may impact on the metabonomic profiles. For example there have been several reported incidences of patients treated with capecitabine developing hypertriglyceridemia which would influence post-therapy profiles obtained (54-58). How these drug effects are treated remains to be considered. In future studies it would also be of interest to investigate impact of chemotherapy on the metabonomic profile by considering pre-and post-treatment NMR spectra, and correlating any change with clinical outcome. Chemotherapy-induced toxicities have direct impact on cancer treatment outcomes including response rates and survival (59). Moreover, adverse effects not only limit the ability of the oncologist to effectively deliver treatment, but they also have a significant negative impact on the patient's quality of life (60-62). It can be argued that a significant level of toxicity is acceptable if the ultimate goal of treatment is cure, however severe treatment related toxicity is unacceptable where the objective of treatment is symptom palliation (63, 64) . The use, therefore, of serum metabonomics as a non-invasive tool for the prediction of toxicity could greatly benefit this patient population and these data require further investigation prospectively in a large clinical trial. The next step in the process of defining a predictive set of markers is to move to a much larger patient cohort to generate predictive models with training and validation sets. In all such predictive studies there remains the challenge of balancing findings identified in populations, e.g. geographical differences in folate intake, versus those derived from the study of inter-individual differences. Our eventual goal is to produce models based on the combination of both pharmaco-genetic and pharmaco-metabonomic information using up-and down-stream data to help delineate the optimum therapeutic pathway for the individual patient(65)(66). 
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Figure 3
Comparison of the mean 1D presaturation and CPMG spectra for each toxicity grade for (A) fatty acid chain, and (B) choline phospholipid spectral regions.
Figure 4
The metabolites that differ significantly between patients that consequently experience no toxicity and those that experience a severe response show intermediate levels in the patients that experience mild and moderate toxicity (grade 1 and 2). In all cases p<0.05 for both Kendall's tau across all toxicity grades, and a T test comparing no toxicity (grade 0) and severe groups (grade 3)
Research. Spectral regions were screened using a T test comparing the patients that experienced no toxicity versus severe toxicity (2 tailed, assuming unequal variance and corrected for multiple testing, q<0.05). These regions were then tested for correlation across all four icity (2 tailed, assuming unequal ity grades using Kendall's tau (rankafter correction for multiple testing;
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